Targeted drug combo tested in stem cell transplant for blood cancers – study stopped early
NCT ID NCT03856216
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 22 times
Summary
This study looked at adding the targeted drug inotuzumab ozogamicin to standard chemotherapy before and after a stem cell transplant for people with certain types of leukemia or lymphoma. The goal was to see if it was safe and could help control the cancer. The study was stopped early after enrolling only 15 people, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.